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Abstract
Background It is not known whether there are differences in the quality and recommendations
between evidence-based (EB) and consensus-based (CB) guidelines. We used breast cancer
guidelines as a case study to assess for these differences.
Methods Five different instruments to evaluate the quality of guidelines were identified by a
literature search. We also searched MEDLINE and the Internet to locate 8 breast cancer guidelines.
These guidelines were classified in three categories: evidence based, consensus based and
consensus based with no explicit consideration of evidence (CB-EB). Each guideline was evaluated
by three of the authors using each of the instruments. For each guideline we assessed the
agreement among 14 decision points which were selected from the NCCN (National Cancer
Comprehensive Network) guidelines algorithm. For each decision point we recorded the level of
the quality of the information used to support it. A regression analysis was performed to assess if
the percentage of high quality evidence used in the guidelines development was related to the
overall quality of the guidelines.
Results Three guidelines were classified as EB, three as CB-EB and two as CB. The EB guidelines
scored better than CB, with the CB-EB scoring in the middle among all instruments for guidelines
quality assessment. No major disagreement in recommendations was detected among the
guidelines regardless of the method used for development, but the EB guidelines had a better
agreement with the benchmark guideline for any decision point. When the source of evidence used
to support decision were of high quality, we found a higher level of full agreement among the
guidelines' recommendations. Up to 94% of variation in the quality score among guidelines could
be explained by the quality of evidence used for guidelines development.
Conclusion EB guidelines have a better quality than CB guidelines and CB-EB guidelines. Explicit
use of high quality evidence can lead to a better agreement among recommendations. However,
no major disagreement among guidelines was noted regardless of the method for their
development.
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The objective of guidelines development is to assist physi-
cians and patients in making optimal health care deci-
sions, which in turn should improve the quality of clinical
practice [1].
Different methods are used to develop guidelines. Some
are developed by a consensus of experts while others also
use a formal way to appraise the literature and create evi-
dence-based (EB) guidelines. In general, evidence-based
guidelines are considered to provide better recommenda-
tions for practice than consensus-based guidelines but are
time consuming and expensive to create [2,3]. This belief
that EB guidelines are superior to other types of guideline
is based on our normative views of methods for guidelines
development [4] and not on empirical comparison of
practice recommendations using different methods for
development of guidelines. To date no formal evaluation
has been performed to detect if there are differences in the
quality and recommendations between evidence-based
and consensus-based (CB) guidelines.
If guidelines developed by using consensus or evidence-
based methods have the same quality and agree in the rec-
ommendations, then obviously resources spent on the la-
borious and time-consuming process of locating and
appraising evidence can be used elsewhere. Otherwise, if
evidence based guidelines have a better quality and their
recommendations differ from those guidelines produced
by consensus, then creation of evidence based guidelines
may become the only acceptable method of guideline de-
velopment.
In this paper, we explore if there are differences in the
quality and recommendations between EB and CB guide-
lines.
Methods
To enable meaningful comparison, multiple recommen-
dations produced by a given guideline method should be
available. This objective is best met by focusing on the
guidelines that comprehensively attempt to guide clini-
cians in the management of one disorder. Since breast
cancer is an important disease and various organizations
have produced guidelines using different methods [5–7],
we conducted a comparison study of comprehensive
breast cancer guidelines. We assessed both the differences
in the quality as measured by using different quality in-
struments assessment and the level of agreement among
guidelines according to the method of development.
1. Identification and assessment of instruments for meas-
urement of the quality of guidelines
Since there is no uniformly accepted instrument for eval-
uation of the quality of guidelines, we first performed a
comprehensive literature search to identify published
tools for assessment of clinical practice guideline quality.
We searched MEDLINE (1996–2000) using the keywords:
guidelines, practice guidelines, quality, "weights and
measures", "scale", psychometrics, reproducibility. Any
article considered relevant to evaluate quality of guide-
lines was retrieved. The list of references of each article
was also scanned. After an assessment of 14 papers by four
of us, four instruments to assess the quality of guidelines
were identified [8–12]. An additional instrument (SIGN)
was identified through Evidence-based Health Discussion
Group (Table 1). For additional details on the instru-
ments for evaluation of guidelines readers are referred to
the Appendix (see 1Additional file). To assess their relia-
bility and reproducibility, we applied all identified instru-
ments to each guideline (see below). We calculated the
coefficient of agreement (kappa) among evaluators for
each guideline [13]. A good interobserver agreement was
considered if kappa value exceeded 0.4 [13]. In our evalu-
ation, two instruments [10,12] had a kappa interobserver
agreement K > 0.4 among all investigators in 6 of 8 guide-
lines (Table 1). When it comes to evaluation of the quality
of breast cancer guidelines these instruments [10,12] per-
formed better than others and probably can be recom-
mended for future use.
2. Identification and classification of breast cancer guide-
lines
A literature search was conducted for published breast
cancer guidelines using MEDLINE for the years 1996 –
April 2000. The following keywords were used in combi-
Table 1: Interobserver agreement of instruments for assessment 
of the guidelines quality
Instrument Guidelines with K > 0.4 among all four 
evaluators
Cluzeau (8) ACCC (19), CMA (7)
Grilli (9) ACCC (19), NHMRC (16), MPS (18)
Sanders(11) None
Petrie (SIGN) (10) NCCN (6), ACCC (19), SIGN (17), ICSI 
(15), MPS (18), SSO (5)
Shaneyfelt 1999 (12) ACCC (19), CMA (7), NHMRC (16), ICSI 
(15), MPS (18), SSO (5)
Acronyms: ACCC – Association of Community Cancer Centers; 
CMA-Canadian Medical Association; ICSI – Institute for Clinical Sys-
tems Improvement; MPS – Multi Professional Societies; NCCN – 
National Comprehensive Cancer Network; NHMRC – The National 
Health and Medical Research Council; SIGN – Scottish Intercollegiate 
Guidelines Network; SSO – Society of Surgical Oncology.Page 2 of 7
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tions, breast neoplasms. An Internet search was also
performed, using the method described by Sanders et al
[11]. 131 articles were retrieved, and reviewed for their
content. We considered any article that fit the definition
of the National Library of Medicine for practice guide-
lines: directions or principles presenting current or future
rules of policy for the health care practitioner to assist him
in patient care decisions regarding diagnosis, therapy, or
related clinical circumstances [14]. Eight papers referred
to breast cancer guidelines [5–7],[15–19] and were select-
ed for the analysis.
Each guideline was classified as CB, when there was no
consideration about the quality of evidence used to make
practice recommendations; as EB, when there was an ex-
plicit consideration of the quality of evidence in the devel-
opment of guidelines; or as consensus based with no
explicit consideration of evidence (CB-EB) when there
were considerations about the evidence, but not in explic-
it manner. From these eight guidelines, three were classi-
fied as EB [17,7,16] three as CB-EB [15,18,6] and two as
CB [19,5] (Table 2).
3. Evaluation of guidelines
Each guideline was evaluated independently by three of
us using each of the instruments. All discordances were re-
solved by a consensus meeting. Each guideline was scored
according to the instructions of each instrument. The
quality and rank was determined by the quotient of items
scored positively by the total items scored for each instru-
ment.
4. Evaluation of agreement among guidelines
Using instruments to evaluate practice guidelines yields
conclusions regarding normative aspects of the guidelines
development [1], but does not necessarily mean that rec-
ommendations provided by guidelines using different
methods will produce different management advice to
our patients. To assess if recommendations among vari-
ous guidelines differ, we need to determine the level of
agreement among guidelines for each specific decision
point.
Since NCCN (National Comprehensive Cancer Network)
guidelines [6] were presented in explicit, algorithmic for-
mat, we used this one to identify the decision points for
matched comparison with other guidelines. These guide-
lines have been developed by the leading 18 cancer insti-
tutions in the US and have been constantly updated and
re-evaluated. They have also been developed to closely
mimic clinical practice. Therefore, we feel that selection of
decision points based on the NCCN guidelines were ap-
propriate. We identified fourteen decision points in the
management of stage I and II breast cancer that were
linked to specific recommendations in the other guide-
lines for our comparison. Comparison of recommenda-
tions for advanced stages of breast cancer has not been
performed since there was only one guideline that includ-
ed it [6].
Table 2: Classification of Breast Cancer Guidelines according to 
the method of development.
Evidence 
Based
Consensus Based with 
no explicit considera-
tion of evidence
Consensus Based
CMA (7) NCCN (6) ACCC(19)
SIGN (17) ICSI (15) SSO (5)
NHMRC(16) MPS(18)
Acronyms: see footnote in Table 1
Table 3: Quality of breast cancer guidelines
Instruments for assessment of guidelines quality
Cluzeau (8) Grilly (9) Sanders (11) Shaneyfelt (12) Petrie (SIGN) 
(10)
Average Score
SIGN(17) 0.94 1.00 1.00 0.84 0.82 0.92
NHMRC(16) 0.77 1.00 1.00 0.80 0.75 0.86
CMA(7) 0.74 1.00 0.93 0.88 0.65 0.84
ICSI(15) 0.77 0.67 1.00 0.64 0.55 0.72
NCCN(6) 0.66 0.67 0.86 0.60 0.44 0.64
MPS(18) 0.37 0.67 0.80 0.40 0.37 0.52
ACCC(19) 0.36 0.00 0.60 0.40 0.32 0.34
SSO(5) 0.18 0.00 0.20 0.20 0.18 0.15
Acronyms: see footnote in Table 1Page 3 of 7
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points in each guideline examining level of agreement
among various guidelines. Since matching between rec-
ommendations in the guidelines that were presented in
non-algorithmic format was poor, we decided to use
NCCN guidelines as a benchmark. We classified agree-
ment of each guideline with the NCCN guidelines as hav-
ing full agreement, partial agreement and disagreement. It
was considered that guidelines agree with the NCCN if the
management recommendation was the same; the guide-
lines were considered to disagree if they provided different
recommendations. A partial agreement was judged to ex-
ist if the guideline recommended the same management
but in a broadly defined sense and not in explicit, clear
manner.
Each of these decision points was also classified as sup-
ported by high quality evidence or not. High quality evi-
dence was considered to be based on randomized trials
(RCT) or systematic reviews (SR)/meta-analysis (MA). If
the quality evidence was not based on RCT or SR/MA or
was not stated, it was classified as low quality evidence.
Subsequently, we performed a regression analysis to as-
sess the contribution of the quality of evidence to the total
score obtained by each instrument for the evaluation of
the guidelines quality. Independent variable was the pro-
portion of decisions supported by high quality evidence
while dependent variable was score obtained by each in-
strument. A regression analysis was performed after it has
assessed that the distribution of the variables was normal
by Wilks-Shapiro test.
Results
Evaluation of the quality of guidelines
The results of the quality of each guideline according to
each instrument are shown in Table 3. Overall, EB guide-
lines had higher scores than CB, and the CB-EB category
ranked in the middle (Fig 1). As expected, the instruments
for the evaluation of quality are based on the number of
desired built-in normative features of good guidelines de-
velopment, as initially recommended by Institute of Med-
icine[1]. This is further confirmed by the evaluation of the
contribution of the quality of evidence to the final quality
score: the regression analysis performed showed that the
quality of guidelines, as measured by these instruments, is
a function of the percentage of high quality evidence that
each guideline contains. This suggests that evidence plays
a major role in the composition of the quality scales. If the
quality of evidence is poor, paying attention to other qual-
ity domains in the development of guidelines will not re-
sult in higher quality scores. Fig 2 illustrates a relationship
between the quality of evidence and the total quality score
using the two instruments that achieved best agreement
among evaluators [10,12]. It is quite remarkable to note
that up to >94% variation in the score could be explained
by the quality of evidence alone.
Evaluation of agreement among guidelines
The agreement among each guideline for the 14 decision
points is shown in Table 4. We obtained no major disa-
greements among guidelines, but the EB guidelines had a
better agreement with the decision points in any situation
than CB-guidelines and CB-EB guidelines. The fact that no
major disagreements were seen regardless the method of
development can probably be explained by the vagueness
of recommendations by CB guidelines. As shown in Table
4, the number of decision points supported by high qual-
ity evidence is highest in the EB guidelines and zero in CB
guidelines. The use of high quality evidence was signifi-
cantly associated with a higher level of concordance
among the decision points. When the source of evidence
was of good quality (RCT or SR), we had 18 full agree-
ments and 23 partial agreements (Chi square = 0.610, de-
grees of freedom = 1, p = 0.435). When the source of
Table 4: Level of agreement between NCCN guideline and other breast cancer guidelines.
Guideline Agreement Partial Agreement Statistical significance (p) N. of decision points with 
high quality evidence
SIGN(17) 5 9 .285 13
NHMRC(16) 8 6 .593 13
CMA(7) 9 5 .285 9
ICSI(15) 4 10 .109 6
NCCN(6) - - - 3
MPS(18) 0 14 <0.0001 0
ACCC(19) 9 5 .285 0
SSO(5) 0 14 <0.0001 0
Acronyms: see footnote table 1Page 4 of 7
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full agreements and 40 partial agreements (Chi-Square
9.281, Degrees of freedom 2, p= 0.002). This means that
recommendations based on high quality evidence may
lead to less disagreement and potentially less practice var-
iation.
Discussion
Guidelines have been increasingly used in medical deci-
sion-making. Different methods have been used in guide-
line development. Does it matter how guidelines were
produced? Most authors believe that it matters very much
[3] and that guidelines produced using evidence-based
methods are superior to other methodologies of develop-
ment [2,4,9]. However, empirical investigations to assess
if guidelines produced by different methods have different
quality and result in different recommendations have not
been performed. Here, we report such a study.
Using formal instruments for evaluation of the quality of
guidelines we found that EB-guidelines had substantially
higher score than CB-guidelines or guideline that consid-
ered evidence in a less formal way (CB-EB). As discussed
above (see Results), this is not a surprising result, since the
instruments for the guidelines evaluation measure the
quality based on the number of desired normative charac-
teristics in a particular guideline. Since appraisal of evi-
dence is considered inherently important for the
development of a good guideline, one would then expect
that the guidelines that pay more attention to its evidence
basis (i.e., those that are evidence-based) would receive
higher quality score than other types of the guidelines (i.e.
guidelines developed solely by a consensus process) (see
Fig 1). This is also evident in our finding that variation in
the total quality score can be up to 94% explained by the
quality of evidence (see Fig 2).
Not all instruments for evaluation of guidelines per-
formed equally well. Only two of the instruments availa-
ble to address the quality of guidelines had a good level of
agreement among evaluators (k > 0.4) in most of guide-
lines. This result raises concern about the reproducibility
of results using the other instruments reported in the liter-
ature. In general, a few studies have been done to evaluate
reproducibility of the instruments for assessment of the
guidelines quality. Any future study attempting to address
the quality of guidelines should take this finding into ac-
count.
A more interesting question is to assess if the recommen-
dations among guidelines produced by different methods
actually differ. We found no instance of total disagree-
ment among guidelines regardless of the method of devel-
opment. We also found that EB and CB-EB guidelines had
more points of agreement with our benchmark guidelines
(NCCN)[6] than guidelines developed using exclusively
consensus method. We also found that when high-quality
evidence existed in the literature (see Results) less disa-
greement was found among various guidelines. This is not
completely surprising because formulation of guidelines
does not happen in a vacuum. Most guideline developers
are experts in the field who have knowledge of the litera-
ture. When evidence is unequivocal, less disagreement
may be expected. Consequently, less practice variation
may be found when high-quality evidence exists.
Conclusions
In conclusion, EB guidelines have a better quality than CB
guidelines as measured by the quality assessment instru-
ments used in this study. The explicit use of high quality
evidence is desirable and can lead to a better agreement
among recommendations. However, no major disagree-
ment among guidelines was noted regardless of the meth-
od for their development.
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Figure 1
Average score of each guideline according to the method of
development Acronyms and abbreviations: ACCC – Associa-
tion of Community Cancer Centers; CMA-Canadian Medical
Association; ICSI – Institute for Clinical Systems Improve-
ment; MPS – Multi Professional Societies; NCCN – National
Comprehensive Cancer Network; NHMRC – The National
Health and Medical Research Council; SIGN – Scottish Inter-
collegiate Guidelines Network; SSO – Society of Surgical
Oncology. EB: evidence-based guidelines; CB: consensus-
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